Education
About Us
Working with TipRanks
Follow Us
Passage Bio, Inc. (PASG)
:PASG
PASG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.35 - $1.64
Previous CloseN/A
Volume182.24K
Average Volume (3M)160.88K
Market Cap
$23.68M
Enterprise Value-$15.77M
Total Cash (Recent Filing)$37.57M
Total Debt (Recent Filing)$25.48M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
May 19, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding62,148,273
10 Day Avg. Volume129,091
30 Day Avg. Volume160,885
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)31.14
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$7.67Price Target Upside1918.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Passage Bio News
PremiumCompany Announcements
Passage Bio Advances Gene Therapy for Neurodegenerative Diseases
PremiumCompany Announcements
Passage Bio Reports 2024 Financial Results and Program Advances
PremiumCompany Announcements
Passage Bio Restructures and Extends Cash Runway---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressThe plan to evaluate a lower dose could further improve the safety profile, and alignment with the FDA on the potency assay is an encouraging step forward on manufacturing.
EarningsPASG's 4Q24 report included a reassuring data point, showing initial plasma neurofilament light chain levels 13% lower at 12 months compared to an expected 29% increase.
Financial PerformanceRestructuring efforts and a transition to an outsourced analytical testing model have extended the cash runway, providing financial stability until the first quarter of 2027.
Bears Say
Operational ChangesA significant headcount reduction as part of restructuring may indicate underlying financial pressures.
Regulatory ChallengesThe waiting period between each patient dosing is now much shorter at 30 days, which could potentially accelerate data collection.
Safety ConcernsA serious adverse event in the first patient of Cohort 2 led to a decision to reduce the dose by 50% for safety and regulatory reasons.
---
Ownership Overview
26.55% Insiders
4.94% Mutual Funds
<0.01% Other Institutional Investors
65.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PASG FAQ
What was Passage Bio, Inc.’s price range in the past 12 months?
Passage Bio, Inc. lowest stock price was $0.35 and its highest was $1.64 in the past 12 months.
What is Passage Bio, Inc.’s market cap?
Passage Bio, Inc.’s market cap is $23.68M.
When is Passage Bio, Inc.’s upcoming earnings report date?
Passage Bio, Inc.’s upcoming earnings report date is May 19, 2025 which is in 49 days.
How were Passage Bio, Inc.’s earnings last quarter?
Passage Bio, Inc. released its earnings results on Mar 04, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.215 by $0.015.
Is Passage Bio, Inc. overvalued?
According to Wall Street analysts Passage Bio, Inc.’s price is currently Undervalued.
Does Passage Bio, Inc. pay dividends?
Passage Bio, Inc. does not currently pay dividends.
What is Passage Bio, Inc.’s EPS estimate?
Passage Bio, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Passage Bio, Inc. have?
Passage Bio, Inc. has 62,148,273 shares outstanding.
What happened to Passage Bio, Inc.’s price movement after its last earnings report?
Passage Bio, Inc. reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.215. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of Passage Bio, Inc.?
Currently, no hedge funds are holding shares in PASG
---
Passage Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (1918.42% Upside)
$7.67 (1918.42% Upside)
Blogger Sentiment
Bullish
PASG Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $6.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.77%
12-Months-Change
Fundamentals
Return on Equity
-75.07%
Trailing 12-Months
Asset Growth
-31.97%
Trailing 12-Months
Company Description
Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
---
PASG Stock 12 Month Forecast
Average Price Target
$7.67
▲(1918.42% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering PASG
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-27.01%
reiterated a buy rating 27 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -27.01% per trade.
---